Donatien Serge Mbaga, Sebastien Kenmoe, Jacky Njiki Bikoï, Guy Roussel Takuissu, Marie Amougou-Atsama, Etienne Atenguena Okobalemba, Jean Thierry Ebogo-Belobo, Arnol Bowo-Ngandji, Martin Gael Oyono, Jeannette Nina Magoudjou-Pekam, Ginette Irma Kame-Ngasse, Alex Durand Nka, Alfloditte Flore Feudjio, Cromwel Zemnou-Tepap, Elie Adamou Velhima, Juliette Laure Ndzie Ondigui, Rachel Audrey Nayang-Mundo, Sabine Aimee Touangnou-Chamda, Yrene Kamtchueng Takeu, Jean Bosco Taya-Fokou, Chris Andre Mbongue Mikangue, Raoul Kenfack-Momo, Cyprien Kengne-Ndé, Carole Stephanie Sake, Seraphine Nkie Esemu, Richard Njouom, Lucy Ndip, Sara Honorine Riwom Essama
{"title":"全球隐蔽性丙型肝炎病毒流行:一项系统综述和荟萃分析。","authors":"Donatien Serge Mbaga, Sebastien Kenmoe, Jacky Njiki Bikoï, Guy Roussel Takuissu, Marie Amougou-Atsama, Etienne Atenguena Okobalemba, Jean Thierry Ebogo-Belobo, Arnol Bowo-Ngandji, Martin Gael Oyono, Jeannette Nina Magoudjou-Pekam, Ginette Irma Kame-Ngasse, Alex Durand Nka, Alfloditte Flore Feudjio, Cromwel Zemnou-Tepap, Elie Adamou Velhima, Juliette Laure Ndzie Ondigui, Rachel Audrey Nayang-Mundo, Sabine Aimee Touangnou-Chamda, Yrene Kamtchueng Takeu, Jean Bosco Taya-Fokou, Chris Andre Mbongue Mikangue, Raoul Kenfack-Momo, Cyprien Kengne-Ndé, Carole Stephanie Sake, Seraphine Nkie Esemu, Richard Njouom, Lucy Ndip, Sara Honorine Riwom Essama","doi":"10.5662/wjm.v12.i3.179","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Occult hepatitis C infection (OCI) is characterized by the presence of hepatitis C virus (HCV) RNA in the liver, peripheral blood mononuclear cells (PBMC) and/or ultracentrifuged serum in the absence of detectable HCV-RNA in serum. OCI has been described in several categories of populations including hemodialysis patients, patients with a sustained virological response, immunocompromised individuals, patients with abnormal hepatic function, and apparently healthy subjects.</p><p><strong>Aim: </strong>To highlight the global prevalence of OCI.</p><p><strong>Methods: </strong>We performed a systematic and comprehensive literature search in the following 4 electronic databases PubMed, EMBASE, Global Index Medicus, and Web of Science up to 6th May 2021 to retrieve relevant studies published in the field. Included studies were unrestricted population categories with known RNA status in serum, PBMC, liver tissue and/or ultracentrifuged serum. Data were extracted independently by each author and the Hoy <i>et al</i> tool was used to assess the quality of the included studies. We used the random-effect meta-analysis model to estimate the proportions of OCI and their 95% confidence intervals (95%CI). The Cochran's <i>Q</i>-test and the <i>I</i> <sup>2</sup> test statistics were used to assess heterogeneity between studies. Funnel plot and Egger test were used to examine publication bias. R software version 4.1.0 was used for all analyses.</p><p><strong>Results: </strong>The electronic search resulted in 3950 articles. We obtained 102 prevalence data from 85 included studies. The pooled prevalence of seronegative OCI was estimated to be 9.61% (95%CI: 6.84-12.73) with substantial heterogeneity [<i>I</i>² = 94.7% (95%CI: 93.8%-95.4%), <i>P</i> < 0.0001]. Seropositive OCI prevalence was estimated to be 13.39% (95%CI: 7.85-19.99) with substantial heterogeneity [<i>I</i> <sup>2</sup> = 93.0% (90.8%-94.7%)]. Higher seronegative OCI prevalence was found in Southern Europe and Northern Africa, and in patients with abnormal liver function, hematological disorders, and kidney diseases. Higher seropositive OCI prevalence was found in Southern Europe, Northern America, and Northern Africa.</p><p><strong>Conclusion: </strong>In conclusion, in the present study, it appears that the burden of OCI is high and variable across the different regions and population categories. Further studies on OCI are needed to assess the transmissibility, clinical significance, long-term outcome, and need for treatment.</p>","PeriodicalId":23729,"journal":{"name":"World journal of methodology","volume":"12 3","pages":"179-190"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/8c/WJM-12-179.PMC9157636.pdf","citationCount":"3","resultStr":"{\"title\":\"Global prevalence of occult hepatitis C virus: A systematic review and meta-analysis.\",\"authors\":\"Donatien Serge Mbaga, Sebastien Kenmoe, Jacky Njiki Bikoï, Guy Roussel Takuissu, Marie Amougou-Atsama, Etienne Atenguena Okobalemba, Jean Thierry Ebogo-Belobo, Arnol Bowo-Ngandji, Martin Gael Oyono, Jeannette Nina Magoudjou-Pekam, Ginette Irma Kame-Ngasse, Alex Durand Nka, Alfloditte Flore Feudjio, Cromwel Zemnou-Tepap, Elie Adamou Velhima, Juliette Laure Ndzie Ondigui, Rachel Audrey Nayang-Mundo, Sabine Aimee Touangnou-Chamda, Yrene Kamtchueng Takeu, Jean Bosco Taya-Fokou, Chris Andre Mbongue Mikangue, Raoul Kenfack-Momo, Cyprien Kengne-Ndé, Carole Stephanie Sake, Seraphine Nkie Esemu, Richard Njouom, Lucy Ndip, Sara Honorine Riwom Essama\",\"doi\":\"10.5662/wjm.v12.i3.179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Occult hepatitis C infection (OCI) is characterized by the presence of hepatitis C virus (HCV) RNA in the liver, peripheral blood mononuclear cells (PBMC) and/or ultracentrifuged serum in the absence of detectable HCV-RNA in serum. OCI has been described in several categories of populations including hemodialysis patients, patients with a sustained virological response, immunocompromised individuals, patients with abnormal hepatic function, and apparently healthy subjects.</p><p><strong>Aim: </strong>To highlight the global prevalence of OCI.</p><p><strong>Methods: </strong>We performed a systematic and comprehensive literature search in the following 4 electronic databases PubMed, EMBASE, Global Index Medicus, and Web of Science up to 6th May 2021 to retrieve relevant studies published in the field. Included studies were unrestricted population categories with known RNA status in serum, PBMC, liver tissue and/or ultracentrifuged serum. Data were extracted independently by each author and the Hoy <i>et al</i> tool was used to assess the quality of the included studies. We used the random-effect meta-analysis model to estimate the proportions of OCI and their 95% confidence intervals (95%CI). The Cochran's <i>Q</i>-test and the <i>I</i> <sup>2</sup> test statistics were used to assess heterogeneity between studies. Funnel plot and Egger test were used to examine publication bias. R software version 4.1.0 was used for all analyses.</p><p><strong>Results: </strong>The electronic search resulted in 3950 articles. We obtained 102 prevalence data from 85 included studies. The pooled prevalence of seronegative OCI was estimated to be 9.61% (95%CI: 6.84-12.73) with substantial heterogeneity [<i>I</i>² = 94.7% (95%CI: 93.8%-95.4%), <i>P</i> < 0.0001]. Seropositive OCI prevalence was estimated to be 13.39% (95%CI: 7.85-19.99) with substantial heterogeneity [<i>I</i> <sup>2</sup> = 93.0% (90.8%-94.7%)]. Higher seronegative OCI prevalence was found in Southern Europe and Northern Africa, and in patients with abnormal liver function, hematological disorders, and kidney diseases. Higher seropositive OCI prevalence was found in Southern Europe, Northern America, and Northern Africa.</p><p><strong>Conclusion: </strong>In conclusion, in the present study, it appears that the burden of OCI is high and variable across the different regions and population categories. Further studies on OCI are needed to assess the transmissibility, clinical significance, long-term outcome, and need for treatment.</p>\",\"PeriodicalId\":23729,\"journal\":{\"name\":\"World journal of methodology\",\"volume\":\"12 3\",\"pages\":\"179-190\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/8c/WJM-12-179.PMC9157636.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of methodology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5662/wjm.v12.i3.179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5662/wjm.v12.i3.179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
摘要
背景:隐匿性丙型肝炎感染(OCI)的特征是肝脏、外周血单核细胞(PBMC)和/或超离心血清中存在丙型肝炎病毒(HCV) RNA,而血清中没有可检测到的HCV-RNA。有几类人群描述了OCI,包括血液透析患者、持续病毒学反应患者、免疫功能低下个体、肝功能异常患者和明显健康的受试者。目的:了解全球OCI的流行情况。方法:系统、全面检索PubMed、EMBASE、Global Index Medicus和Web of Science 4个电子数据库,检索截至2021年5月6日在该领域发表的相关研究。纳入的研究是在血清、PBMC、肝组织和/或超离心血清中已知RNA状态的无限制人群类别。数据由每位作者独立提取,并使用Hoy等工具评估纳入研究的质量。我们使用随机效应荟萃分析模型来估计OCI的比例及其95%置信区间(95% ci)。采用Cochran’s q检验和i2检验统计量来评估研究间的异质性。采用漏斗图和Egger检验检验发表偏倚。所有分析均采用R软件4.1.0版本。结果:电子检索结果3950篇。我们从85项纳入的研究中获得102项患病率数据。血清OCI阴性的总患病率估计为9.61% (95%CI: 6.84-12.73),具有显著的异质性[I²= 94.7% (95%CI: 93.8%-95.4%), P < 0.0001]。血清OCI阳性患病率估计为13.39% (95%CI: 7.85-19.99),存在显著异质性[i2 = 93.0%(90.8%-94.7%)]。在南欧和北非,以及肝功能异常、血液学疾病和肾脏疾病的患者中,血清阴性OCI患病率较高。在南欧、北美和北非发现了较高的血清阳性OCI患病率。结论:总体而言,在本研究中,不同地区和人群类型的OCI负担较高且存在差异。需要进一步的研究来评估OCI的传播性、临床意义、长期结局和治疗的必要性。
Global prevalence of occult hepatitis C virus: A systematic review and meta-analysis.
Background: Occult hepatitis C infection (OCI) is characterized by the presence of hepatitis C virus (HCV) RNA in the liver, peripheral blood mononuclear cells (PBMC) and/or ultracentrifuged serum in the absence of detectable HCV-RNA in serum. OCI has been described in several categories of populations including hemodialysis patients, patients with a sustained virological response, immunocompromised individuals, patients with abnormal hepatic function, and apparently healthy subjects.
Aim: To highlight the global prevalence of OCI.
Methods: We performed a systematic and comprehensive literature search in the following 4 electronic databases PubMed, EMBASE, Global Index Medicus, and Web of Science up to 6th May 2021 to retrieve relevant studies published in the field. Included studies were unrestricted population categories with known RNA status in serum, PBMC, liver tissue and/or ultracentrifuged serum. Data were extracted independently by each author and the Hoy et al tool was used to assess the quality of the included studies. We used the random-effect meta-analysis model to estimate the proportions of OCI and their 95% confidence intervals (95%CI). The Cochran's Q-test and the I2 test statistics were used to assess heterogeneity between studies. Funnel plot and Egger test were used to examine publication bias. R software version 4.1.0 was used for all analyses.
Results: The electronic search resulted in 3950 articles. We obtained 102 prevalence data from 85 included studies. The pooled prevalence of seronegative OCI was estimated to be 9.61% (95%CI: 6.84-12.73) with substantial heterogeneity [I² = 94.7% (95%CI: 93.8%-95.4%), P < 0.0001]. Seropositive OCI prevalence was estimated to be 13.39% (95%CI: 7.85-19.99) with substantial heterogeneity [I2 = 93.0% (90.8%-94.7%)]. Higher seronegative OCI prevalence was found in Southern Europe and Northern Africa, and in patients with abnormal liver function, hematological disorders, and kidney diseases. Higher seropositive OCI prevalence was found in Southern Europe, Northern America, and Northern Africa.
Conclusion: In conclusion, in the present study, it appears that the burden of OCI is high and variable across the different regions and population categories. Further studies on OCI are needed to assess the transmissibility, clinical significance, long-term outcome, and need for treatment.